

LYNPARZA EXPERT ON DEMAND PROGRAMME

MEETING PACKAGE BROCHURE

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting <https://contactazmedical.astrazeneca.com> or by calling 0800 783 0033.

Prescribing information and adverse event reporting for UK can be found [here](#).
This is a promotional material developed and funded by AstraZeneca and MSD.
This material is for UK healthcare professionals only.
This is a digital material not intended to be printed.

GB-65220 | DOP: July 2025



CONTENTS

Why & how to request an EOD session	3
EOD session delivery method	3
Available topics	4
EOD speaker biographies	5
Licensed indications	8

EoD=Expert on Demand.

WHY BOOK AN EXPERT ON DEMAND SESSION?

The Expert on Demand (EoD) programme simplifies learning opportunities by bringing UK experts in advanced ovarian cancer (aOC) to you through novel, interactive virtual presentations and Q&A sessions on multiple relevant topics.

The “on demand” nature offers a personalised approach to education across a range of promotional subject matters regarding Lynparza treatment and associated topics relating to aOC.

There is no requirement to travel as the meeting takes place via a virtual platform, and can be joined from your own professional workplace.

HOW DO I REQUEST AN EOD SESSION?

Please speak to your local MSD Account Manager to request an EoD session with one of the expert speakers listed in this brochure.

The account manager will then submit your request and schedule the session using an online platform hosted by AstraZeneca and MSD’s vendor partner, Distance Learning Providers (DLP).



You will receive notifications via the DLP platform and will be notified of the required dial-in details in advance of the session.

WHAT IS THE FORMAT OF AN EOD SESSION?

You can request a 1:1 or small group session with an expert healthcare professional to discuss a particular topic of interest to you (see following pages for an overview of the available topics) via your local MSD Account Manager.

PERSONAL

**1:1 or small
Group presentations**

PROFESSIONAL

**Expert speakers
with relevant experience**

PRACTICAL

**~30 minutes
presentation with Q&A**

For any queries, please contact your local AZ/MSD account manager or benjamin.bracke@astrazeneca.com

AVAILABLE TOPICS

TOPIC

EoD EXPERT SPEAKERS

Expanding beyond BRCA into HRD positive: The PAOLA-1 regimen

Increase your understanding of the Lynparza plus bevacizumab regimen (PAOLA-1) in eligible HRD-positive patients, ensuring you provide your patients with a suitable treatment within your local setting and make their first-line maintenance treatment count.



Dr Joo-Ern Ang
Consultant Medical Oncologist, Cambridge University Hospitals NHS Foundation Trust



Dr Laura Tookman
Consultant medical oncologist specialising in gynae-oncology at Imperial College NHS Trust



Dr Roshan Agarwal
Consultant Medical Oncologist, Three Shires Hospital, Northamptonshire

The PAOLA-1 regime: A case study of advanced ovarian cancer management

Go beyond the PAOLA-1 trial and review case studies based on patients from the UK. Discover how multidisciplinary teams (MDTs) collectively assess the patient journey as well as the decision-making processes which are followed to improve patient outcomes.



Dr Saira Khalique
Consultant Medical Oncologist, Mount Vernon Cancer Centre and Hillingdon Hospital



Dr Jurjees Hasan
Consultant Medical Oncologist, The Christie Cancer Centre

Surgical management: Assessing first-line treatment options in advanced ovarian cancer

Understand the latest insights from surgical interventions in advanced ovarian cancer (aOC), and how these are tailored to fit the unique needs of each patient group. Uncover how surgical decisions fit into patient care, influence outcomes and guide the choice of maintenance treatments in aOC.



Prof. Christina Fotopoulou
Consultant Gynaecological Oncologist, Queen Charlotte's & Chelsea Hospital

HRD testing: A step forward in personalised care in advanced ovarian cancer

Gain insight into best practice guidelines for HRD testing in the UK. Learn how to integrate HRD testing into your clinical practice and increase your understanding of HRD and its relation to PARP inhibitor (PARPi) maintenance effectiveness for aOC.



Dr Rowan Miller
Consultant Medical Oncologist, University College London and St Bartholomew's Hospitals



Dr Rebecca Bowen
Consultant Medical Oncologist, Royal United Hospitals Bath NHS Foundation Trust



Prof. Julian Barwell
Consultant in Clinical Genetics, University of Leicester

Supporting patients with advanced ovarian cancer through PARP inhibitor clinics

Extend your focus beyond treatment to embrace the full spectrum of support for patients undergoing PARPi therapy for aOC. Learn about the benefits of nurse-led clinics and understand the process of setting these up within your local trust.



Ms Gemma Roth
Clinical nurse specialist in gynaecological oncology at the Northern Centre for Cancer Care

EOD SPEAKER BIOGRAPHIES



Dr Joo-Ern Ang

Dr Ang is a Consultant Medical Oncologist based at Cambridge University Hospitals NHS Foundation Trust, with a subspecialty interest in gynaecology. Dr Ang obtained his undergraduate degree at the University of Cambridge and completed specialist training in North Thames and at the Royal Marsden Hospital in London. Dr Ang has extensive experience in the clinical development of novel anticancer agents and cancer biomarkers and is the Principal Investigator (PI) of several clinical trials at Cambridge as well as the current National Institute for Health Research Clinical Research Network lead for gynaecology in the Eastern region. He has co-authored numerous peer-reviewed publications and is actively involved in clinical trials and research. Relevant to this Expert on Demand (EoD) series, Dr Ang has substantial experience of the use of PARP inhibitors as monotherapy and in combination with other systemic therapies.



Dr Roshan Agarwal

Dr Agarwal is a Consultant Medical Oncologist specialising in gastro-intestinal and gynaecological malignancies, and cancers of unknown primary. He was Senior Lecturer in Oncology at Imperial College London, before moving to Northampton General Hospital as Lead for Oncology Research, Acute Oncology and Cancer of Unknown Primary services in 2013. Dr Agarwal is passionate about delivering excellent holistic cancer care, and divides his time between direct clinical patient care, clinical trials and a research programme focused on the identification of novel clinically useful biomarkers and targeted therapies in cancer. He has published over 70 peer-reviewed research papers and book chapters, in journals such as Lancet, Lancet Oncology, Journal of Clinical Oncology, Nature Reviews Cancer and Science Translational Medicine.



Dr Saira Khalique

Dr Khalique qualified from University of St Andrews and Manchester University and undertook clinical training at The Christie, Manchester, The Edinburgh Cancer Centre and University College London hospitals (UCLH). Her PhD, based at the Institute of Cancer Research and The Royal Marsden focused on identifying new therapeutic strategies in ovarian clear cell carcinoma. She is the National Cancer Research Institute (NCRI) Early Career Research Lead for the Head and Neck Group focused on translational collaborations for clinical trials, Honorary Senior Lecturer at Brunel University, London, and a member of the UK NCRI Ovarian group. As a Medical Oncology Consultant at Mount Vernon Cancer Centre, she is focused on setting up clinical trials and is UK Chief Investigator/Principal Investigator (PI) for head and neck studies and PI for gynaecological cancer studies. She has published research articles, reviews, and book chapters.

EOD SPEAKER BIOGRAPHIES CONTINUED



Dr Jurjees Hasan

Dr Hasan graduated in India following which, he moved to the UK to undertake his specialist training. He was appointed to the post of Medical Oncologist at The Christie NHS Foundation Trust in 2005.

Dr Hasan's subspecialty interests include gynaecological malignancies, colorectal cancer and carcinoma of unknown primary site. Dr Jurjees Hasan is a Lead Medical Oncologist for gynaecological malignancies and covers the southern sector of the Greater Manchester Cancer Network. He also supports Outreach chemotherapy at Stepping Hill Hospital where he has developed a chemotherapy service for colorectal cancers.

Dr Hasan has served as Principle Investigator in Phase II and Phase III studies in gynaecological and colorectal cancer. He is actively involved in programmes to develop HIPEC with cytoreductive surgery for ovarian cancer, management of malignant bowel obstruction and molecular oncology to support personalised targeted therapies. Dr Hasan's work has been published in peer reviewed journals and presented at international oncology meetings. He has served on various NICE panels and referees manuscripts for publication in oncology journals.



Prof. Christina Fotopoulou

As Chair of the Guidelines Committee of the British Gynaecological Cancer Society, Prof. Fotopoulou has developed the British guidelines for the treatment of ovarian - cervical, endometrial and vulva cancer. She is an elected council member of the European Society of Gynaecologic Oncology (ESGO) and is the current Chair of the Guidelines Committee of ESGO. She has been active in the development, validation and establishment of Surgical Quality assurance Programmes across Europe and in the accreditation of Centres of Excellence for ovarian cancer surgery. Her research focus is on the tumour heterogeneity of epithelial ovarian cancer and how tumour biology interacts with surgical effort. She is on the editorial board and reviewer in numerous international gynaecological and oncological journals.



Dr Rowan Miller

Dr Miller is a Consultant Medical Oncologist specialising in gynae-oncology and early phase clinical trials at University College London and St Bartholomew's Hospitals. Her research interests include novel therapies for gynaecological cancer and utilising genomics and biomarkers to guide therapy in patients, particularly in early-phase clinical trials. Dr Miller completed her undergraduate training at the University of Oxford and clinical training at Guy's and St Thomas' Hospitals, London. She trained in Medical Oncology at University College London and was subsequently awarded a Cancer Research UK Fellowship and attained a PhD from the Institute of Cancer Research. Following her PhD, Dr Miller completed a fellowship at Dana Farber Cancer Institute, Harvard University. Dr Miller is involved in a number of clinical trials and basic science research projects across the two academic centres and is a member of the European Society for Medical Oncology (ESMO) Personalised Medicine and Translational Research Committee.

HIPEC=Hyperthermic (or Heated) Intraperitoneal Chemotherapy; NICE=National Institute for Health and Care Excellence.

EOD SPEAKER BIOGRAPHIES CONTINUED



Dr Rebecca Bowen

Dr Bowen is a Medical Oncologist at the Royal United Hospital, Bath, specialising in breast and gynaecological cancers and leads a multidisciplinary oncology menopause service. She is currently the Clinical and Research lead in Bath and visiting professor at the University of Bath. She is the Deputy Chair of the National Cancer Research Institute (NCRI) Gynaecological Group and the Clinical Research Specialty Lead for Gynae-Oncology for the West of England. Dr Bowen is Co-chair for the UK Gynae-Oncologist Meeting and a member of the UK Breast Cancer Group.



Prof. Julian Barwell

Prof Barwell trained at Guy's and St Thomas' Hospitals in Medicine with an intercalated BSc in Basic Medical Sciences and Human Genetics. After finishing his Clinical Genetics training at Guy's, St George's and the Royal Marsden from the University of London, he started as a consultant in Clinical Genetics in Leicester in 2007. Prof. Barwell has sat on the Breast Cancer Now grant advisory board, helped launch the 100,000 genome project on the British broadcast (BBC) Breakfast sofa and sits on the NHS Genomics Ethics, Equity and Legal Advisory Group. He is also a national clinical advisor to the National Hereditary Breast Cancer Helpline and is clinical lead of the United Against Prostate Cancer project, establishing tumour BRCA testing.

Prof. Barwell is a joint Clinical Lead of the Paediatric and Genetics Clinical Research Facility at the Leicester Royal infirmary and is establishing a fragile X syndrome research group and patient self-navigation projects with the Genomic Medicine Service Alliance. He is a Senior Author of Clinical Genetics and Genomics at a Glance as well as a children's book called 'What is DNA?'. He was awarded an honorary chair (professorship) by the University of Leicester in 2015.



Dr Laura Tookman

Dr Laura Tookman is a consultant medical oncologist specialising in gynae-oncology at Imperial College NHS Trust. Dr Tookman completed her undergraduate training at the University of Cambridge and clinical training at University College London Medical School. She trained in medical oncology at St Bartholomew's and University College Hospitals London. Her PhD research, at Barts Cancer Institute, investigated a novel treatment for ovarian cancer and was funded by the Medical Research Council. Dr Tookman is involved in a number of clinical trials and research projects. She has a particular interest in projects aimed at developing the service for patients with gynaecological malignancies.



Ms Gemma Roth

Ms Gemma Roth is a clinical nurse specialist in gynaecological oncology at the Northern Centre for Cancer Care. She obtained her nursing qualification from Kingston University before beginning her career at the Royal Marsden Hospital, London. Gemma's big passions lie within holistic care and she has extensive experience in the management of patients on parp inhibitor maintenance treatment. She obtained her prescribing qualification in 2025 and in her current role runs 4 nurse led clinics including surveillance, on treatment and PARP inhibitor clinics.

LICENSED INDICATIONS

Lynparza (olaparib) tablets

Advanced ovarian cancer indications¹

1) Lynparza tablets are indicated as a monotherapy for the:

maintenance treatment of adult patients with advanced (FIGO stages III and IV) *BRCA1/2*-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy

2) Lynparza tablets in combination with bevacizumab are indicated for the:

maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a *BRCA1/2* mutation and/or genomic instability

Always refer to the Summaries of Product Characteristics before prescribing to minimise the risks associated with the use of these medicines.

FOR HEALTHCARE PROFESSIONAL USE ONLY.

Please note that this is for digital use only and may not be printed.

This material is fully funded and developed by AstraZeneca and MSD.

FIGO=International Federation of Gynecology and Obstetrics; HRD=homologous recombination deficiency.

1. Lynparza (olaparib) Summary of Product Characteristics.